Rational Design of Affinity Improvement of Dengue 4e11 Antibody

Exclusively Licensed

The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV.

Researchers

Ram Sasisekharan / Kannan Tharakaraman / Luke Robinson

Departments: School of Engineering
Technology Areas: Diagnostics: Assays / Drug Discovery and Research Tools: Antibodies / Therapeutics: Proteins & Antibodies
Impact Areas: Healthy Living

  • anti-dengue virus antibodies and uses thereof
    Spain | Granted | 2,882,453
  • anti-dengue virus antibodies and uses thereof
    United States of America | Granted | 9,499,607
  • anti-dengue virus antibodies and uses thereof
    Sri Lanka | Granted | 18,103
  • anti-dengue virus antibodies and uses thereof
    Mexico | Granted | 366,886
  • anti-dengue virus antibodies and uses thereof
    European Patent Convention | Granted | 2,882,453
  • anti-dengue virus antibodies and uses thereof
    Australia | Granted | 2,018,203,152
  • anti-dengue virus antibodies and uses thereof
    Japan | Granted | 6,605,643
  • rational design of affinity improvement of dengue 4e11 antibody
    Mexico | Granted | 410,163
  • anti-dengue virus antibodies and uses thereof
    Singapore | Granted | 11,201,500,605
  • anti-dengue virus antibodies and uses thereof
    Canada | Granted | 2,879,994
  • anti-dengue virus antibodies and uses thereof
    Japan | Granted | 6,297,560
  • anti-dengue virus antibodies and uses thereof
    Israel | Granted | 236,838
  • anti-dengue virus antibodies and uses thereof
    Brazil | Granted | 112,015,002,605
  • anti-dengue virus antibodies and uses thereof
    Australia | Granted | 2,013,299,986
  • anti-dengue virus antibodies and uses thereof
    China | Granted | 104,768,574
  • anti-dengue virus antibodies and uses thereof
    Korea (south) | Granted | 10
  • anti-dengue virus antibodies and uses thereof
    Hong Kong | Granted | 1,210,054
  • anti-dengue virus antibodies and uses thereof
    Hong Kong | Granted | 1,211,851
  • anti-dengue virus antibodies and uses thereof
    United States of America | Granted | 9,880,167
  • anti-dengue virus antibodies and uses thereof
    Germany | Granted | 2,882,453
  • anti-dengue virus antibodies and uses thereof
    United Kingdom | Granted | 2,882,453
  • anti-dengue virus antibodies and uses thereof
    France | Granted | 2,882,453
  • anti-dengue virus antibodies and uses thereof
    Italy | Granted | 2,882,453

License this technology

Interested in this technology? Connect with our experienced licensing team to initiate the process.

Sign up for technology updates

Sign up now to receive the latest updates on cutting-edge technologies and innovations.

More Technologies